Revolution Medicines starts Phase 3 trial of zoldonrasib for lung cancer

October 20, 2026 8:01 AM

Revolution Medicines, Inc. (Nasdaq: RVMD) announced it has begun treating patients in RASolve 308, a global Phase 3 clinical trial ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found